Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 7, 2026

Back to the front page

From X

@aleabitoreddit

Serenity on X

"Potential FCC rules on optical transceivers more likely to come at 3.2T" - $LITE, $AAOI, $COHR, $SIVE. Morgan Stanley met with Washington officials: - Restrictions would likely start at 3.2T modules made in China (800g/1.6T would be left alone) - Potential restrictions would likely keep laser market tight (combining US DSPs + lasers could meet the 65% US value threshold per MS) - Chinese modules could qualify if 65% of bill of materials is US content. Chinese modules using US DSPs and lasers are already near that level - Analysts expect the positive impact on laser pricing... to be more important than any broad redistribution of transceiver market share. - Analysts don't expect this to bottleneck hyperscaler AI buildouts, they name InP substrate supply as the key variable to watch (hello $AXTI ) TLDR: Component suppliers in general are really positive. Like $SMTC probably winner here for TIAs/drivers (I don't think this was listed), maybe $MXL for DSPs too. $AAOI another large beneficiary. $SIVE is high-key alpha for laser beneficaries since they have "tremendous capacity" coming online, and that points to US foundries (they haven't formally disclosed location). Since previous slideshows show 2 US foundries 1 Taiwan foundry (Win Semi) in terms of their capacity partnerships. And it's process of elimination. From CIOE Channel checks it does look like they're starting to work with Chinese pluggable players, (so they'd avenues moving forward as US supply chain component beneficiaries). Of course $LITE / $COHR would be happy. TLDR: Western supply chains for Lasers / DSPs / TIAs / others are already bottlenecked but qualified capacity becomes even more important.
@KEDM_COM

KEDM.com on X

Qiagen $QGEN has a new CEO (Jonathan Pratt) per Sept. 1. Let's see if he can bring some action. The company also recently confirmed it continues to evaluate strategic alternatives, with Goldman Sachs involved. There have been reports of takeover interest for a long time, with past reports linking Qiagen to Thermo Fisher, bioMérieux, and Bio-Rad. Qiagen is an interesting target given its leadership in nucleic acid prep, strong consumables-driven revenue, and growth areas like TB testing and digital PCR. The portfolio would fit well with major industry consolidators.

Investor Letters

All letters

Axon 3Q26 Business Update

Axon cut full-year guidance after delayed federal Dedrone contracts slowed 3Q revenue growth to 28%, while software and services grew 43%.

AXON $31B
Speedwell Memos 3 clicks

ARM Q2 FY3/27 Earnings Review

Arm reported Q2 revenue of $1.443 billion, up 27%, as licensing rose 50% while royalties grew 8%; Q3 guidance calls for $1.54 billion.

ARM $181B
Cestrian Capital Research

AppLovin 3Q26: Business Update

AppLovin's 3Q26 revenue rose 55% year over year and margins reached 78.2%, driven by AXON model gains, while publisher bidding pressure…

APP $118B
Speedwell Memos 2 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 278

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.